An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial
An Tran-Duy, Marjan Ghiti Moghadam, Martijn AH Oude Voshaar, Harald E Vonkeman, Annelies Boonen, Philip Clarke, Geoff McColl, Peter M ten Klooster, TR Zijlstra, Willem F Lems, N Riyazi, EN Griep, JMW Hazes, Robert Landewe, Hein J Bernelot Moens, Piet LCM van Riel, Mart AFJ van de Laar, TL Jansen
ARTHRITIS & RHEUMATOLOGY | WILEY | Published : 2018
OBJECTIVE: To evaluate, from a societal perspective, the incremental cost-effectiveness of withdrawing tumor necrosis factor inhibitor (TNFi) treatment compared to continuation of these drugs within a 1-year, randomized trial among rheumatoid arthritis patients with longstanding, stable disease activity or remission. METHODS: Data were collected from a pragmatic, open-label trial. Cost-utility analysis was performed using the nonparametric bootstrapping method, and a cost-effectiveness acceptability curve was constructed using the net-monetary benefit framework, where a willingness-to-accept threshold (WTA) was defined as the minimal cost saved that a patient accepted for each quality-adjust..View full abstract
Awarded by Government of The Netherlands, Ministry of Health, Welfare and Sport
Supported by The Netherlands Organization for Health Research and Development and the Government of The Netherlands, Ministry of Health, Welfare and Sport (grant 40-00506-98-12001).